Zydus Lifesciences is currently trading at Rs. 368.65, up by 2.85 points or 0.78% from its previous closing of Rs. 365.80 on the BSE.
The scrip opened at Rs. 367.00 and has touched a high and low of Rs. 372.90 and Rs. 365.00 respectively. So far 17857 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 651.75 on 13-Jul-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 372.90 and Rs. 358.20 respectively. The current market cap of the company is Rs. 37950.14 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 14.88% and 10.24% respectively.
Zydus Lifesciences has launched the molecule Sitagliptin in India under the brand names Sitaglyn and Siglyn to address Type 2 diabetes in India. Sitaglyn and Siglyn will add on to a comprehensive solution for the management of Type 2 diabetes by providing access to quality care to the patients at an affordable cost, approximately 60% lesser than the originator.
Sitaglyn and Siglyn offer an oral solution to the patients providing ease of convenience and better compliance. Sitagliptin is the gold standard in the Dipeptidyl peptidase 4 inhibitor (DPP4i) category with over 62% market share in the global market. The drug provides best in class achievement of Hemoglobin A1C (HbA1c) goals with proven safety profile.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.